User profiles for K. L. Lanctot
Krista LanctotSunnybrook Research Institute, University of Toronto Verified email at sunnybrook.ca Cited by 32113 |
Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits
Objectives To quantify and compare potential benefits (subjective reports of sleep variables)
and risks (adverse events and morning-after psychomotor impairment) of short term …
and risks (adverse events and morning-after psychomotor impairment) of short term …
Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis
KL Lanctôt, N Herrmann, KK Yau, LR Khan, BA Liu… - Cmaj, 2003 - Can Med Assoc
… Lanctôt and Herrmann conceived and designed the study and contributed substantially to …
Lanctôt received research honoraria and/or speaker fees and/or travel assistance from Pfizer, …
Lanctôt received research honoraria and/or speaker fees and/or travel assistance from Pfizer, …
Peripheral alterations in cytokine and chemokine levels after antidepressant drug treatment for major depressive disorder: systematic review and meta-analysis
Mounting evidence suggests that aberrations in immune-inflammatory pathways contribute
to the pathophysiology of major depressive disorder (MDD), and individuals with MDD may …
to the pathophysiology of major depressive disorder (MDD), and individuals with MDD may …
A meta-analysis of cytokines in major depression
…, W Swardfager, H Liu, L Sham, EK Reim, KL Lanctôt - Biological …, 2010 - Elsevier
BACKGROUND: Major depression occurs in 4.4% to 20% of the general population. Studies
suggest that major depression is accompanied by immune dysregulation and activation of …
suggest that major depression is accompanied by immune dysregulation and activation of …
Peripheral cytokine and chemokine alterations in depression: a meta‐analysis of 82 studies
…, CL Raison, BJ Miller, KL Lanctôt… - Acta Psychiatrica …, 2017 - Wiley Online Library
Objective To conduct a systematic review and meta‐analysis of studies that measured cytokine
and chemokine levels in individuals with major depressive disorder ( MDD ) compared to …
and chemokine levels in individuals with major depressive disorder ( MDD ) compared to …
Neuropsychiatric symptoms in Alzheimer's disease: past progress and anticipation of the future
Neuropsychiatric symptoms (NPS) in Alzheimer's disease (AD) are widespread and disabling.
This has been known since Dr. Alois Alzheimer's first case, Frau Auguste D., presented …
This has been known since Dr. Alois Alzheimer's first case, Frau Auguste D., presented …
Peripheral inflammatory markers in Alzheimer's disease: a systematic review and meta-analysis of 175 studies
KSP Lai, CS Liu, A Rau, KL Lanctôt… - Journal of Neurology …, 2017 - jnnp.bmj.com
Objectives Increasing evidence suggests that inflammation is involved in Alzheimer’s disease
(AD) pathology. This study quantitatively summarised the data on peripheral inflammatory …
(AD) pathology. This study quantitatively summarised the data on peripheral inflammatory …
[HTML][HTML] Neuropsychiatric signs and symptoms of Alzheimer's disease: New treatment paradigms
KL Lanctôt, J Amatniek, S Ancoli-Israel… - Alzheimer's & Dementia …, 2017 - Elsevier
Neuropsychiatric symptoms (NPSs) are hallmarks of Alzheimer's disease (AD), causing
substantial distress for both people with dementia and their caregivers, and contributing to early …
substantial distress for both people with dementia and their caregivers, and contributing to early …
[HTML][HTML] Perspectives on ethnic and racial disparities in Alzheimer's disease and related dementias: update and areas of immediate need
…, LA Johnson, R Jutten, K Kilborn, KL Lanctôt… - Alzheimer's & …, 2019 - Elsevier
Alzheimer's disease and related dementias (ADRDs) are a global crisis facing the aging
population and society as a whole. With the numbers of people with ADRDs predicted to rise …
population and society as a whole. With the numbers of people with ADRDs predicted to rise …
[HTML][HTML] The Mild Behavioral Impairment Checklist (MBI-C): a rating scale for neuropsychiatric symptoms in pre-dementia populations
…, N Herrmann, J Kanji, KL Lanctôt… - Journal of Alzheimer's …, 2017 - ncbi.nlm.nih.gov
Background Mild Behavioral Impairment (MBI) is a construct that describes the emergence
at≥ 50 years of age of sustained and impactful neuropsychiatric symptoms (NPS), as a …
at≥ 50 years of age of sustained and impactful neuropsychiatric symptoms (NPS), as a …